Actively Recruiting
Is a Third Dose of Measles-mumps-rubella-(Varicella) Vaccine (MMR(V)) Vaccine Beneficial for the Adult Population in Alberta?
Led by University of Alberta · Updated on 2026-03-16
200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of Alberta
Lead Sponsor
M
Merck Canada Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating the immune response to a third dose of the measles-mumps-rubella-(varicella) vaccine (MMR(V)) in adult women in Alberta. The study focuses on women who have low antibody levels after receiving the standard two doses, as current antibody tests may not fully reflect immunity. This research aims to better understand whether a third dose improves protection, especially important for prenatal populations at risk of congenital infections. This observational study includes women who have already received a third dose of the MMR(V) vaccine as part of their routine healthcare. Participants are divided into groups based on their rubella antibody levels, either below or above the protective threshold. The study measures both antibody levels and cell-mediated immune (CMI) responses to measles, mumps, rubella, and varicella before and after the third vaccine dose. Participants will undergo blood tests to assess their antibody and CMI responses at baseline and after the third dose. Researchers will track changes in rubella antibody levels over 12 months to evaluate the immune response. This study does not administer vaccines but observes the immune status of women who have been vaccinated through standard care. The total duration of participation varies based on timing of these assessments.
CONDITIONS
Brief Title
Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women who are pregnant and have undergone routine prenatal screening for rubella antibodies.
You will not qualify if you...
- Women younger than 18 years of age
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Baseline
Participants have blood tests to measure rubella IgG antibody levels and assess cell mediated immune (CMI) responses before any additional vaccination.
1 visit (in-person)
Duration - Up to 12 months
Participants who receive a third dose of MMR vaccine through routine healthcare are observed with follow-up blood tests to measure changes in antibody levels and CMI responses.
2 visits (in-person) - one post third dose and one follow-up within 12 months
Trial Site Locations
Total: 1 location
1
University of Alberta
Edmonton, Alberta, Canada, T6G2R3
Actively Recruiting
Research Team
C
Carmen Charlton, PhD
M
Michael H Mengel
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here